Translate this page into:
Authors’ response
* For correspondence: nairvelu2000@yahoo.com
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
We thank Deepa Bhartiya for her comments on our article published resently1.
We have the following comments:
-
This study was firstly not undertaken based on the results of the pilot ABCD study reported from AIIMS, New Delhi, as suggested by Deepa Bhartiya. Our study was based on an extensive Cochrane review2 of all relevant published literature on this subject at that point of time.
-
This phase III prospective, open labelled, randomized multicenteric trial was conducted from 2007 to 2010 and only relevant issues were highlighted in the discussion pertaining to the trial period. Hence, the contention that no articles published from 2013-2015 having been cited should not be surprising. At no stage, even remotely, have we suggested that no progress has been made in this field as mentioned in the letter3. On the contrary, we agree that significant progress has been made in the field of stem cells and mesenchymal stem cells (MSC) worldwide.
-
Regarding the point raised about MSCs ability to differentiate into cardiac cells we would like to highlight that MSCs have already been differentiated in vitro using different growth factors and chemicals into cardiomyocytes and neurons45.
-
The author's remaining comments mostly are not relevant to our article as she has discussed extensively on VSELs. However, as is known it has its own controversies in the scientific literature.
References
- Efficacy of stem cell in improvement of left ventricular function in acute myocardial infarction-M13 Trial. Indian J Med Res. 2015;142:165-74.
- [Google Scholar]
- Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;2:CD006536.
- [Google Scholar]
- National multicentric M13 Stem Cell Trial reports negative outcome - Need to look at VSELs as an alternative to bone marrow MNCs for cardiac regeneration. Indian J Med Res. 2016;143:830-2.
- [Google Scholar]
- Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood). 2004;229:623-31.
- [Google Scholar]
- TGFβ1 contributes to cardiomyogenic - like differentiation of human bone marrow mesenchymal stem cells. Int J Cardiol. 2013;163:93-9.
- [Google Scholar]
